NASDAQ$JAGX
Jaguar Health Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Jaguar Health's prescription revenues increased significantly, driven by Mytesi growth and Canalevia-CA1 commercial availability.
Jaguar Health reported a 57% increase in prescription product net revenue for Q4 2022 compared to Q4 2021, reaching $3.3 million. The growth was attributed to the continued success of Mytesi and the introduction of Canalevia-CA1. The company is focused on expanding clinical trials and exploring new indications for crofelemer.
- Prescription product net revenue increased by 57% in Q4 2022 compared to Q4 2021.
- Mytesi revenue continued to grow for the sixth consecutive quarter.
- Patient enrollment in the OnTarget Phase 3 clinical trial is at approximately 80% and expected to complete in Q2 2023.
- The company plans to support investigator-initiated proof-of-concept studies of crofelemer for short bowel syndrome and congenital diarrheal disorders.
Headline financials
Revenue & EPS history
Jaguar Health · Revenue · Quarterly
$3.26M
Revenue by segment
Jaguar Health · $20.3M total across 2 segments · Q1 2026
- Human Health$19.9M—98.3%
- Animal Health$345K—1.7%
Forward guidance
Jaguar Health is focused on completing enrollment in the OnTarget trial, supporting investigator-initiated studies, and submitting an IND application for crofelemer.
Tailwinds
- Patient enrollment in OnTarget trial expected to complete in Q2 2023.
- Planning to support investigator-initiated proof-of-concept studies of crofelemer in 2023.
- Potential early patient access to crofelemer in Europe in 2024.
- Plans to submit an IND application in Q2 2023 to FDA for crofelemer for microvillus inclusion disease.
- Transition to limited distribution network of specialty pharmacies resulted in a meaningful reduction in Mytesi distribution costs as well as a higher average net price
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2022
-6.2%
Avg return
Earnings day
-10.0%
Avg return
5 days after
-12.3%
Avg return
30 days after
24%
11 / 45 earnings
Positive
+23.1%
Q3 2023
Best reaction
-36.4%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.4% | -9.6% | — | |
| Q1 2026 | -5.0% | -13.6% | -37.9% | |
| Q3 2025 | +2.9% | -32.0% | -33.1% | |
| Q2 2025 | -17.9% | -25.9% | -24.3% | |
| Q1 2025 | +4.8% | -22.5% | -36.5% | |
| Q4 2024 | +8.8% | -12.6% | +144.8% | |
| Q3 2024 | -4.6% | -10.2% | -11.1% | |
| Q2 2024 | -10.8% | +5.8% | -7.5% | |
| Q1 2024 | -12.2% | -10.7% | -78.7% | |
| Q4 2023 | -17.8% | -6.7% | +150.0% | |
| Q3 2023 | +23.1% | +31.3% | -46.1% | |
| Q2 2023 | -10.8% | -12.6% | -44.9% | |
| Q1 2023 | -31.7% | -32.2% | -28.6% | |
| Q4 2022 | -31.0% | -44.4% | -51.3% | |
| Q3 2022 | -6.7% | -13.3% | -25.3% | |
| Q2 2022 | -8.8% | -8.6% | -32.6% | |
| Q1 2022 | -7.1% | -1.4% | -15.5% | |
| Q4 2021 | -7.4% | +12.8% | +42.5% | |
| Q3 2021 | -16.7% | -20.7% | -35.1% | |
| Q2 2021 | -12.8% | -15.0% | -34.8% | |
| Q1 2021 | -2.4% | +4.7% | +37.8% | |
| Q4 2020 | +13.8% | +14.4% | -13.2% | |
| Q3 2020 | -5.9% | +2.0% | +108.4% | |
| Q2 2020 | -21.3% | -15.3% | -36.5% | |
| Q1 2020 | -1.4% | -0.4% | -1.4% | |
| Q4 2019 | -5.9% | -6.5% | +2.0% | |
| Q3 2019 | -36.4% | -37.9% | -45.0% | |
| Q2 2019 | -23.9% | -27.7% | -16.4% | |
| Q1 2019 | +0.6% | +4.1% | -60.4% | |
| Q4 2018 | -9.8% | -23.9% | -38.6% | |
| Q3 2018 | -4.3% | -8.5% | -33.2% | |
| Q2 2018 | -12.4% | -19.9% | -50.3% | |
| Q1 2018 | -4.4% | -5.7% | -26.6% | |
| Q4 2017 | +4.6% | -1.1% | -9.3% | |
| Q3 2017 | -2.4% | -5.0% | -32.2% | |
| Q2 2017 | -6.3% | -15.4% | -19.7% | |
| Q1 2017 | -1.2% | -0.4% | -16.4% | |
| Q4 2016 | -1.1% | +10.3% | +16.1% | |
| Q3 2016 | -1.9% | -18.8% | -15.8% | |
| Q2 2016 | +3.4% | -6.1% | -23.1% | |
| Q1 2016 | +0.6% | — | — | |
| Q4 2015 | +5.6% | — | — | |
| Q3 2015 | +8.0% | — | — | |
| Q2 2015 | -1.7% | — | — | |
| Q1 2015 | -7.4% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro